Nemaura Medical (NMRD)
(Delayed Data from OTC)
$0.03 USD
0.00 (-12.47%)
Updated Jul 12, 2024 03:55 PM ET
NA Value
NA Growth NA Momentum NA VGMFundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
NMRD 0.03 0.00(-12.47%)
Will NMRD be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for NMRD based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for NMRD
Nemaura (NMRD) to Expand in UK With Metabolic Health Program
DexCom (DXCM) Q3 Earnings and Revenues Surpass Estimates
NMRD: What are Zacks experts saying now?
Zacks Private Portfolio Services
Nemaura Medical, Inc. (NMRD) Upgraded to Buy: What Does It Mean for the Stock?
Nemaura Medical, Inc. (NMRD) Reports Q3 Loss, Lags Revenue Estimates
Nemaura Medical, Inc. (NMRD) Reports Q2 Loss, Misses Revenue Estimates
Other News for NMRD
Twelve option delistings on June 24th